A European-based investor group has launched a campaign to persuade the board of Aurinia Pharmaceuticals Inc to carry out a strategic review of the US-listed drug developer.
This is paywall protected Betaville Intelligence content. You need to purchase a subscription to access this content. Or get in touch with subscription sales at [email protected] to find out about the different subscription packages on offer.
